Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC
Clinical trial NCT05244837 · UNKNOWN
Trial details
- NCT number
- NCT05244837
- Sponsor
- Hao Long
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-22
- Primary completion
- 2022-07-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.